Management of thrombotic and cardiovascular disorders in the new millenium

Clinical and Applied Thrombosis/Hemostasis

Volumn 9, Issue 2, 2003, Pages 101-108

  Fareed, Jawed ^a   Hoppensteadt, Debra A ^b   Bick, Rodger L ^b  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

Anti Xa agents; Antiplatelet agents; Antithrombin agents; Cardiovascular disorders; Heparin; Low molecular weight heparin; Thrombotic

Indexed keywords

2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; ABCIXIMAB; ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; ANTITHROMBIN; ANTITHROMBOCYTIC AGENT; ARGATROBAN; BIOVALIRUDIN; BLOOD CLOTTING FACTOR 10A INHIBITOR; CILOSTAZOL; CLOPIDOGREL; DALTEPARIN; DROTRECOGIN; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; FONDAPARINUX; HEPARIN; HIRUDIN; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; MC 977; MELAGATRAN; NADROPARIN; SARPOGRELATE; TICLOPIDINE; TIROFIBAN; UNINDEXED DRUG; XIMELAGATRAN; YM 337;

ARTICLE; BLEEDING; BLOOD CLOTTING TIME; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG COST; DRUG EFFICACY; DRUG SAFETY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; MULTIINFARCT DEMENTIA; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; THROMBOCYTOPENIA; THROMBOSIS; UNSTABLE ANGINA PECTORIS;

EID: 0038725465     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602960300900202     Document Type: Article

References (6)

1. Fareed J, Lewis B, Callas D, Hoppensteadt DA, Walenga JM, Bick R. Antithrombin agents: The new class of anticoagulant and antithrombin drug. Clin Appl Thromb Hemost 1999;5:S45.
2. Fareed J, Haas S, Sasahara A. Differentiation of low molecular weight heparins: Applied and clinical considerations. Sem Thromb Hemost 1999;25:1.
3. Fareed J, Messmore HL. Clopidogrel, a new ADP receptor antagonist: Clinical development. Sem Thromb Hemost 1999;25:1.
4. Fareed J, Walenga JM, Hoppensteadt D, Kaiser B, Jeske W. Factor Xa inhibitors in the control of thrombogenesis. Haemostasis 1999;19:55.
5. Bick RL, Fareed J. Low molecular weight heparins: Differences and similarities in approved preparations in the United States. Clin Appl Thromb Hemost 1999;5:S63.
6. Fareed J, Hoppensteadt D. The management of thrombotic and cardiovascular disorders in the 21st century. In: New Therapeutic Agents in Thrombosis and Thrombolysis. Sasahara, Loscalzo, eds. New York: Marcel Dekker, USA. 2003:687.